150 research outputs found

    Anesthetic Isoflurane Increases Phosphorylated Tau Levels Mediated by Caspase Activation and AĪ² Generation

    Get PDF
    Anesthetic isoflurane has been shown to promote Alzheimerā€™s disease (AD) neuropathogenesis by inducing caspase activation and accumulation of Ī²-amyloid (AĪ²). Phosphorylation of tau protein is another important feature of AD neuropathogenesis. However, the effects of isoflurane on phosphorylated tau levels remain largely to be determined. We therefore set out to determine whether isoflurane can increase phosphorylated tau levels. 5 to 8 month-old wild-type and AD transgenic mice [B6.Cg-Tg (APPswe, PSEN1dE9)85Dbo/J] were treated with 1.4% isoflurane for two hours. The mice brain tissues were harvested at six, 12 and 24 hours after the anesthesia. For the in vitro studies, primary neurons from wild-type and the AD transgenic mice were exposed to 2% isoflurane for six hours, and were harvested at the end of anesthesia. The harvested brain tissues and neurons were subjected to Western blot analysis by which the levels of phosphorylated tau protein at Serine 262 (Tau-PS262) were determined. Here we show that the isoflurane anesthesia increased Tau-PS262 levels in brain tissues and primary neurons from the wild-type and AD transgenic mice. Moreover, the isoflurane anesthesia may induce a greater increase in Tau-PS262 levels in primary neurons and brain tissues from the AD transgenic mice. Finally, caspase activation inhibitor Z-VAD and AĪ² generation inhibitor L-685,458 attenuated the isoflurane-induced increases in Tau-PS262 levels. In conclusion, clinically relevant isoflurane anesthesia increases phosphorylated tau levels, which may result from the isoflurane-induced caspase activation and AĪ² generation. These findings will promote more studies to determine the effects of anesthetics on tau phosphorylation

    RNA interference-mediated silencing of BACE and APP attenuates the isoflurane-induced caspase activation

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Ī²-Amyloid protein (AĪ²) has been shown to potentiate the caspase-3 activation induced by the commonly used inhalation anesthetic isoflurane. However, it is unknown whether reduction in AĪ² levels can attenuate the isoflurane-induced caspase-3 activation. We therefore set out to determine the effects of RNA interference-mediated silencing of amyloid precursor protein (APP) and Ī²-site APP-cleaving enzyme (BACE) on the levels of AĪ² and the isoflurane-induced caspase-3 activation.</p> <p>Methods</p> <p>H4 human neuroglioma cells stably transfected to express full-length human APP (H4-APP cells) were treated with small interference RNAs (siRNAs) targeted at silencing BACE and APP for 48 hours. The cells were then treated with 2% isoflurane for six hours. The levels of BACE, APP, and caspase-3 were determined using Western blot analysis. Sandwich Enzyme-linked immunosorbent assay (ELISA) was used to determine the extracellular AĪ² levels in the conditioned cell culture media.</p> <p>Results</p> <p>Here we show for the first time that treatment with BACE and APP siRNAs can decrease levels of BACE, full-length APP, and APP c-terminal fragments. Moreover, the treatment attenuates the AĪ² levels and the isoflurane-induced caspase-3 activation. These results further suggest a potential role of AĪ² in the isoflurane-induced caspase-3 activation such that the reduction in AĪ² levels attenuates the isoflurane-induced caspase-3 activation.</p> <p>Conclusion</p> <p>These findings will lead to more studies which aim at illustrating the underlying mechanism by which isoflurane and other anesthetics may affect Alzheimer's disease neuropathogenesis.</p
    • ā€¦
    corecore